205 related articles for article (PubMed ID: 25535649)
1. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy.
Mehta AM; Van den Hoven JM; Rosing H; Hillebrand MJ; Nuijen B; Huitema AD; Beijnen JH; Verwaal VJ
Int J Pharm; 2015 Feb; 479(1):23-7. PubMed ID: 25535649
[TBL] [Abstract][Full Text] [Related]
2. Standard Clinical Protocol for Bidirectional Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Systemic Leucovorin, 5-Fluorouracil, and Heated Intraperitoneal Oxaliplatin in a Chloride-Containing Carrier Solution.
Mehta AM; Huitema AD; Burger JW; Brandt-Kerkhof AR; van den Heuvel SF; Verwaal VJ
Ann Surg Oncol; 2017 Apr; 24(4):990-997. PubMed ID: 27896510
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic Effects of Oxaliplatin Instability in Chloride-Containing Carrier Fluids on the Hyperthermic Intraperitoneal Chemotherapy to Treat Colorectal Cancer In Vitro and In Vivo.
Park EJ; Ahn J; Abuzar SM; Park KS; Hwang SJ; Baik SH
Ann Surg Oncol; 2022 Dec; 29(13):8583-8592. PubMed ID: 36042101
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model.
Park EJ; Ahn J; Gwak SW; Park KS; Baik SH; Hwang SJ
Ann Surg Oncol; 2018 Oct; 25(11):3185-3192. PubMed ID: 30027459
[TBL] [Abstract][Full Text] [Related]
5. Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients.
Pérez-Ruixo C; Peris JE; Escudero-Ortiz V; Bretcha-Boix P; Farré-Alegre J; Pérez-Ruixo JJ; Valenzuela B
Cancer Chemother Pharmacol; 2014 May; 73(5):1009-20. PubMed ID: 24663502
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.
Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2013 Mar; 71(3):693-704. PubMed ID: 23274396
[TBL] [Abstract][Full Text] [Related]
7. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols.
Löffler MW; Schuster H; Zeck A; Quilitz N; Weinreich J; Tolios A; Haen SP; Horvath P; Löb S; Rammensee HG; Königsrainer I; Königsrainer A; Beckert S
Ann Surg Oncol; 2017 Jun; 24(6):1650-1657. PubMed ID: 28160138
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis.
Hubert J; Thiboutot E; Dubé P; Cloutier AS; Drolet P; Sideris L
Surg Oncol; 2015 Mar; 24(1):41-6. PubMed ID: 25680983
[TBL] [Abstract][Full Text] [Related]
10. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
[TBL] [Abstract][Full Text] [Related]
11. Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin.
Ceelen W; De Somer F; Van Nieuwenhove Y; Vande Putte D; Pattyn P
Eur J Surg Oncol; 2013 Jul; 39(7):754-9. PubMed ID: 22878060
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
13. Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin.
Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
AAPS J; 2016 Jan; 18(1):239-50. PubMed ID: 26577587
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis.
Ceelen WP; Peeters M; Houtmeyers P; Breusegem C; De Somer F; Pattyn P
Ann Surg Oncol; 2008 Feb; 15(2):535-41. PubMed ID: 17960463
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer.
Gervais MK; Dubé P; McConnell Y; Drolet P; Mitchell A; Sideris L
J Surg Oncol; 2013 Dec; 108(7):438-43. PubMed ID: 24018983
[TBL] [Abstract][Full Text] [Related]
16. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
Vaira M; Robella M; Mellano A; Sottile A; De Simone M
Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
[TBL] [Abstract][Full Text] [Related]
17. High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study.
Facy O; Al Samman S; Magnin G; Ghiringhelli F; Ladoire S; Chauffert B; Rat P; Ortega-Deballon P
Ann Surg; 2012 Dec; 256(6):1084-8. PubMed ID: 22634898
[TBL] [Abstract][Full Text] [Related]
18. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
[TBL] [Abstract][Full Text] [Related]
19. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands.
Razenberg LG; van Gestel YR; Creemers GJ; Verwaal VJ; Lemmens VE; de Hingh IH
Eur J Surg Oncol; 2015 Apr; 41(4):466-71. PubMed ID: 25680955
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis.
Marcotte E; Dubé P; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Sideris L
World J Surg Oncol; 2014 Nov; 12():332. PubMed ID: 25380618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
